Physician profile

Maureen E Parker

Adult Health (Nurse Practitioner) · Littleton, CO

NPI 1346466869

$172.26

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$51.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $29.25 2021-2023 Recarbrio, Zerbaxa
Gilead Sciences, INC. $23.60 2021
Genentech USA, INC. $22.22 2023 Ocrevus
Sanofi Pasteur INC. $22.12 2021
Biohaven Pharmaceuticals, INC. $17.62 2021
Horizon Therapeutics Plc $15.20 2021
Astrazeneca Pharmaceuticals LP $14.39 2023 Fasenra
Pfizer INC. $14.30 2021
Sunovion Pharmaceuticals INC. $13.56 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maureen E Parker

$172.26

in general payments reported 2019-2025

Years
2021-2023
Top company
Merck Sharp & Dohme LLC

https://glasscript.com/doctor/10653679/maureen-e-parker

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.